Category Archives: Brain metastases

New ALK inhibitor reported

According to the article summary, current ALK inhibitors do not inhibit the G1202R mutant of the ALK gene, which is one of the most common mutations. The researchers announced the development of a structural analogue of Alectinib (called JH-VIII-157-02) that … Continue reading

Posted in Brain metastases, Glioblastomas, JH-VIII-157-02, Lung cancer, Neuroblastomas, Potential Treatments, Research, Resistance to treatment | Leave a comment

Survey of ALK inhibitors effects on brain mets

This survey summarizes the results of other research to describe the current level of knowledge about how effective different ALK inhibitors are at treating brain mets. Inhibitors that are discussed include crizotinib, ceritinib, alectinib, AP26113 (brigatinib) and PF-06463922 (lorlatinib). http://www.thecco.net/article/view/6520/7543

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

ALK and brain mets

A study entitled “Extened Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell lung Cancer and Brain Metastasis” was published online October 5, 2015 in the Journal of Clinical Oncology. The lead author was Joseph N. Contessa from Yale. The … Continue reading

Posted in Brain metastases, Lung cancer, Potential Treatments, Research | Leave a comment

Ariad’s Brigatinib trial

Ariad has fully enrolled the Phase 2 trial for Brigatinib. It is likly that it is much harder to get into the trial now. I have not heard of them giving ethical exemptions yet. http://investor.ariad.com/mobile.view?c=118422&v=203&d=1&id=2087810

Posted in AP26113 - brigatinib from Ariad, Brain metastases, Lung cancer, Potential Treatments, Research | Leave a comment

Roche/Genentech to file NDA in 2015

Back in May 14, 2015, Roche announced its plans to file a new drug application for Alectinib in 2015. http://www.roche.com/media/store/releases/med-cor-2015-05-14.htm According to several postings on Inspire.com by patients, Alectinib approval by the FDA is expected by the end of October. … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment

Ariad plans to file NDA in 3rd quarter of 2016

Ariad plans to file a new drug application (NDA) for brigatnib in 3rd quarter of 2016. http://investor.ariad.com/mobile.view?c=118422&v=203&d=1&id=2075920

Posted in AP26113 - brigatinib from Ariad, Brain metastases, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment

Comparison of 3 ALK inhibitors’ phase 2 trials

All of these results are based on 5 phase 2 trials. However the conditions of each trial may differ in important ways. For example, it is my understanding that the trial for brigatinib was limited to healthier patients while the … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

3 Ceritinib abstracts

Abstracts 8060, 8059, and 8058 relate to Ceritinib. Please see glossary for acronym definitions. Abstract 8060 covers the Ascend 3 trial, which is a phase 2 trial that includes ALK inhibitor naive patients. As of 6-27-2014 the trial had 124 … Continue reading

Posted in Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

3 Alectinib abstracts

Here is a summary of abstracts 8061, 8019, and 8008. Please see glossary for acronym definitions. Abstract 8061 is an update on a phase 1/2 trial of 46 Crizotinib naïve patients in Japan. As of 10-31-2014, median PFS has not … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, Lung cancer, Potential Treatments, Research | Leave a comment

Brigatinib Phase 1/2 trial abstract

Abstract 8062 is about a Phase 1/2 trial. There were 137 treated patients (evaluated for safety) and 72 ALK+ patients (evaluated for efficacy). The patients recieved three different dose levels/combinations.  Please see glossary for acronym definitions. As of 8-4-2014, 71% … Continue reading

Posted in AP26113 - brigatinib from Ariad, Brain metastases, Lung cancer, Potential Treatments, Research | Leave a comment